WO2011036297A3 - Method for the therapy and diagnosis of alzheimer's disease - Google Patents

Method for the therapy and diagnosis of alzheimer's disease Download PDF

Info

Publication number
WO2011036297A3
WO2011036297A3 PCT/EP2010/064289 EP2010064289W WO2011036297A3 WO 2011036297 A3 WO2011036297 A3 WO 2011036297A3 EP 2010064289 W EP2010064289 W EP 2010064289W WO 2011036297 A3 WO2011036297 A3 WO 2011036297A3
Authority
WO
WIPO (PCT)
Prior art keywords
alzheimer
diagnosis
therapy
disease
membrane
Prior art date
Application number
PCT/EP2010/064289
Other languages
German (de)
French (fr)
Other versions
WO2011036297A2 (en
Inventor
Helmut E. Meyer
Original Assignee
Ruhr-Universität-Bochum
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ruhr-Universität-Bochum filed Critical Ruhr-Universität-Bochum
Priority to EP10757220A priority Critical patent/EP2504024A2/en
Publication of WO2011036297A2 publication Critical patent/WO2011036297A2/en
Publication of WO2011036297A3 publication Critical patent/WO2011036297A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

The invention relates to a method for the therapy and diagnosis of Alzheimer's disease, comprising receptor tyrosine kinases and/or membrane-bound cytokine receptors, including involved autoimmune antibodies.
PCT/EP2010/064289 2009-09-27 2010-09-27 Method for the therapy and diagnosis of alzheimer's disease WO2011036297A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP10757220A EP2504024A2 (en) 2009-09-27 2010-09-27 Method for the therapy and diagnosis of alzheimer's disease

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09171429 2009-09-27
EP09171429.5 2009-09-27

Publications (2)

Publication Number Publication Date
WO2011036297A2 WO2011036297A2 (en) 2011-03-31
WO2011036297A3 true WO2011036297A3 (en) 2011-10-20

Family

ID=43447835

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2010/064289 WO2011036297A2 (en) 2009-09-27 2010-09-27 Method for the therapy and diagnosis of alzheimer's disease

Country Status (2)

Country Link
EP (1) EP2504024A2 (en)
WO (1) WO2011036297A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2989158B1 (en) 2012-04-04 2014-04-18 Commissariat Energie Atomique METHOD OF MAKING A HEAT EXCHANGER MODULE HAVING AT LEAST TWO FLUID CIRCULATION CIRCUITS.
EP3128326B1 (en) * 2014-04-03 2018-03-14 Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology Biomarker for diagnosis of aging or amyotrophia
WO2017050976A1 (en) * 2015-09-23 2017-03-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Ephb2 polypeptides and uses thereof for the diagnosis and treatment of lupus
CN116626294A (en) * 2022-09-20 2023-08-22 菲创生物医学技术(广州)有限公司 Use of discoid domain receptor 2 in diagnosis of neurodegenerative diseases and related computer readable media

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995030326A1 (en) * 1994-04-29 1995-11-09 Mount Sinai Hospital Corporation Neural receptor tyrosine kinase
WO1997021811A2 (en) * 1995-12-15 1997-06-19 Regeneron Pharmaceuticals, Inc. Novel tyrosine kinase receptors and ligands
US5656473A (en) * 1993-07-21 1997-08-12 Regeneron Pharmaceuticals, Inc. Human Dmk receptor
WO1998045708A1 (en) * 1997-04-08 1998-10-15 Sugen, Inc. Study and treatment of diseases related to specific cellular functions of receptor protein tyrosine kinases
WO1999064589A1 (en) * 1998-06-11 1999-12-16 Astrazeneca Ab Human receptor tyrosine kinase
WO2004063362A2 (en) * 2003-01-10 2004-07-29 Cyclacel Limited Cell cycle progression proteins
US20060199226A1 (en) * 2005-03-02 2006-09-07 Schiffer Hans H Functional bioluminescence energy resonance transfer (BRET) assay to screen, identify and characterize receptor tyrosine kinase ligands
US20070128633A1 (en) * 2005-10-11 2007-06-07 Chembridge Research Laboratories, Inc. Cell-free protein expression systems and methods of use thereof
DE102006048201A1 (en) * 2006-10-11 2008-04-17 Ganymed Pharmaceuticals Ag Autoantigens for the improved diagnosis, prognosis and treatment of inflammatory neurological diseases
WO2009092049A1 (en) * 2008-01-17 2009-07-23 Irm Llc Improved anti-trkb antibodies
WO2009100859A1 (en) * 2008-02-14 2009-08-20 F. Hoffmann-La Roche Ag Prediction of bone marrow toxicity

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6346413B1 (en) 1989-06-07 2002-02-12 Affymetrix, Inc. Polymer arrays
US6406921B1 (en) 1998-07-14 2002-06-18 Zyomyx, Incorporated Protein arrays for high-throughput screening

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5656473A (en) * 1993-07-21 1997-08-12 Regeneron Pharmaceuticals, Inc. Human Dmk receptor
WO1995030326A1 (en) * 1994-04-29 1995-11-09 Mount Sinai Hospital Corporation Neural receptor tyrosine kinase
WO1997021811A2 (en) * 1995-12-15 1997-06-19 Regeneron Pharmaceuticals, Inc. Novel tyrosine kinase receptors and ligands
WO1998045708A1 (en) * 1997-04-08 1998-10-15 Sugen, Inc. Study and treatment of diseases related to specific cellular functions of receptor protein tyrosine kinases
WO1999064589A1 (en) * 1998-06-11 1999-12-16 Astrazeneca Ab Human receptor tyrosine kinase
WO2004063362A2 (en) * 2003-01-10 2004-07-29 Cyclacel Limited Cell cycle progression proteins
US20060199226A1 (en) * 2005-03-02 2006-09-07 Schiffer Hans H Functional bioluminescence energy resonance transfer (BRET) assay to screen, identify and characterize receptor tyrosine kinase ligands
US20070128633A1 (en) * 2005-10-11 2007-06-07 Chembridge Research Laboratories, Inc. Cell-free protein expression systems and methods of use thereof
DE102006048201A1 (en) * 2006-10-11 2008-04-17 Ganymed Pharmaceuticals Ag Autoantigens for the improved diagnosis, prognosis and treatment of inflammatory neurological diseases
WO2009092049A1 (en) * 2008-01-17 2009-07-23 Irm Llc Improved anti-trkb antibodies
WO2009100859A1 (en) * 2008-02-14 2009-08-20 F. Hoffmann-La Roche Ag Prediction of bone marrow toxicity

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LOPEZ O L ET AL: "SERUM AUTOANTIBODIES IN PATIENTS WITH ALZHEIMER'S DISEASE AND VASCULAR DEMENTIA AND IN NONDEMENTED CONTROL SUBJECTS", STROKE, LIPPINCOTT WILLIAMS & WILKINS, US, vol. 23, no. 8, 1 January 1992 (1992-01-01), pages 1078 - 1083, XP009085324, ISSN: 0039-2499 *
PERDIVARA IRINA ET AL: "Glycosylation profiles of epitope-specific anti-beta-amyloid antibodies revealed by liquid chromatography-mass spectrometry", GLYCOBIOLOGY, vol. 19, no. 9, September 2009 (2009-09-01), pages 958 - 970, XP002621663, ISSN: 0959-6658 *

Also Published As

Publication number Publication date
WO2011036297A2 (en) 2011-03-31
EP2504024A2 (en) 2012-10-03

Similar Documents

Publication Publication Date Title
HUS1800047I1 (en) Human cgrp receptor binding antibodies
WO2009128963A3 (en) Cross-neutralizing human monoclonal antibodies to sars-cov and methods of use thereof
SMT201700102B (en) HUMAN ANTIBODIES OF HIGH AFFINITY AT THE RECEPTOR ACTIVATED BY THE HUMAN PROTEASIS-2
WO2009137843A9 (en) Nmda receptor antagonists for the treatment of neuropsychiatric disorders
MY155621A (en) Axl antibodies
WO2010004204A3 (en) Fgf-r4 receptor-specific antagonists
WO2008100805A3 (en) Anti-robo4 antibodies and uses therefor
EP2215049A4 (en) P2x3, receptor antagonists for treatment of pain
AP2012006343A0 (en) Neutralizing prolactin receptor antibodies and their therapeutic use.
WO2010128407A3 (en) Anti-il-17f antibodies and methods of use thereof
EP2358371A4 (en) P2x3, receptor antagonists for treatment of pain
WO2011044311A3 (en) Generation, characterization and uses thereof of anti-her 3 antibodies
WO2011147982A3 (en) Monoclonal antibodies against her2 epitope
WO2010081679A3 (en) Antibodies against human epo receptor
MX2011011825A (en) Humanized axl antibodies.
WO2009021293A8 (en) Agents and methods for modulating macrophage inhibitory cytokine (mic-1) activity
SI1729753T1 (en) Use of an nmda receptor antagonist for the treatment of tinnitus induced by cochlear excitotoxicity
TN2011000463A1 (en) Composition and methods for increasing muscle growth
WO2011080209A3 (en) Antibody formulation
WO2007114861A3 (en) Il-21 receptor antagonists
EP2826791A3 (en) Humanized anti-C5aR antibodies
EA201001253A1 (en) N, N-DESIGNED AMINOALKYLBIPHENYLES AS ANTAGONISTS OF PROSTAGLANDIN RECEPTORS D
WO2013188448A3 (en) Dual receptor antagonistic antigen-binding proteins and uses thereof
WO2012103360A3 (en) Wnt compositions and methods of use thereof
WO2008089022A3 (en) Cd200 and its receptor, cd200r, modulate bone mass via the differentiation of osteoclasts

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10757220

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2010757220

Country of ref document: EP